Pricey Drug Cuts Cardiovascular Risk — But Will Insurers Pay?

Mar 17, 2017, 10:33 by Michael Croft

STAT | Amgen's cholesterol drug lowered risk of cardiovascular trouble in a huge clinical trial - but the results may not be good enough for insurers to cover.

March 17, 2017 | Amgen's cholesterol drug lowered risk of cardiovascular trouble in a huge clinical trial - but the results may not be good enough for insurers to cover. STAT